(Q37678183)

21 August 2017

1 reference

title

Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop (English)

1 reference

21 August 2017

0 references

0 references

1 reference

Jean-Michel Pawlotsky

6

object named as

Jean-Michel Pawlotsky

1 reference

21 August 2017

2

Robert T Schooley

1 reference

21 August 2017

4

Mark S Sulkowski

1 reference

21 August 2017

Alexander Monto

1

1 reference

21 August 2017

Jennifer C Lai

3

1 reference

21 August 2017

Raymond T Chung

5

1 reference

21 August 2017

John G McHutchison

7

1 reference

21 August 2017

Ira M Jacobson

8

1 reference

21 August 2017

language of work or name

English

0 references

publication date

19 January 2010

1 reference

The American Journal of Gastroenterology

21 August 2017

published in

1 reference

21 August 2017

volume

105

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

989-1004; quiz 988, 1005

1 reference

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Antiviral drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Modelling viral and immune system dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Hepatitis B virus biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Dynamics of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

In vitro models for studying hepatitis B virus drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Hepatitis B: reflections on the current approach to antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The culture of designing hepato-biliary randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Mutation rates among RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Nucleoside analogues and mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

An oligonucleotide microarray for multiplex real-time PCR identification of HIV-1, HBV, and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.726

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.726

1 reference

21 August 2017

1 reference